TY - JOUR
T1 - Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells
AU - Kim, Jae Chul
AU - Kim, Jae Sung
AU - Saha, Debabrata
AU - Cao, Qianwen
AU - Shyr, Yu
AU - Choy, Hak
N1 - Funding Information:
This study was supported by a grant from Bristol-Myers Squibb Company (Princeton, NJ 08543, USA).
PY - 2003/9
Y1 - 2003/9
N2 - Background and purpose: To evaluate a semisynthetic epothilone B, BMS-247550, as a potential radiosensitizer in vitro and in vivo. Materials and methods: Human NCI-H460 lung cancer cells were treated with either BMS-247550 or paclitaxel and in combination with radiation at multiple doses for different time periods. Surviving fractions were then analyzed using a clonogenic assay. Cell cycle redistribution by BMS-247550 was measured with propidium iodide and flow cytometry. Percent apoptosis was also measured using 7-amino-actinomycin D staining with flow cytometry. For in vivo studies, the H460 xenograft model was used in athymic nude mice. Tumors were treated with BMS-247550 (5 mg/kg) i.p. injection on days 0, 2, and 4 and/or radiation (2 Gy/day, days 0-4). Results: The in vitro radiation dose enhancement ratios (DER) of 1-h BMS-247550 and paclitaxel were 2.03 and 1.34, respectively. Treatment with BMS-247550 enhanced the G2/M block and induced apoptosis; whereas in combination with radiation, the induction of apoptosis was additive. BMS-247550 in combination with radiation in vivo enhanced the tumor growth delay when compared with either drug or radiation alone. Conclusions: These results demonstrated that BMS-247550 could enhance the effects of radiation in human lung cancer cells both in vitro and in vivo and that a G2/M block and increased apoptosis might be possible explanations for the enhancement.
AB - Background and purpose: To evaluate a semisynthetic epothilone B, BMS-247550, as a potential radiosensitizer in vitro and in vivo. Materials and methods: Human NCI-H460 lung cancer cells were treated with either BMS-247550 or paclitaxel and in combination with radiation at multiple doses for different time periods. Surviving fractions were then analyzed using a clonogenic assay. Cell cycle redistribution by BMS-247550 was measured with propidium iodide and flow cytometry. Percent apoptosis was also measured using 7-amino-actinomycin D staining with flow cytometry. For in vivo studies, the H460 xenograft model was used in athymic nude mice. Tumors were treated with BMS-247550 (5 mg/kg) i.p. injection on days 0, 2, and 4 and/or radiation (2 Gy/day, days 0-4). Results: The in vitro radiation dose enhancement ratios (DER) of 1-h BMS-247550 and paclitaxel were 2.03 and 1.34, respectively. Treatment with BMS-247550 enhanced the G2/M block and induced apoptosis; whereas in combination with radiation, the induction of apoptosis was additive. BMS-247550 in combination with radiation in vivo enhanced the tumor growth delay when compared with either drug or radiation alone. Conclusions: These results demonstrated that BMS-247550 could enhance the effects of radiation in human lung cancer cells both in vitro and in vivo and that a G2/M block and increased apoptosis might be possible explanations for the enhancement.
UR - http://www.scopus.com/inward/record.url?scp=1542781317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542781317&partnerID=8YFLogxK
U2 - 10.1016/S0167-8140(03)00200-7
DO - 10.1016/S0167-8140(03)00200-7
M3 - Article
C2 - 13129641
AN - SCOPUS:1542781317
SN - 0167-8140
VL - 68
SP - 305
EP - 313
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 3
ER -